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e-mail address: monaabdelkader78@yahoo.com (M. Abdelkader).Mona Abdelkader a,⇑, Shereen Ezzelregal Alashry bAbstractBackground: Xanthelasma palpebrarum is the most common of the xanthomas with asymptomatic, symmetrical, bilateral, soft, yel-
low, polygonal papules around the eyelids. Though it is a benign lesion causing no functional disturbance, it is esthetically annoy-
ing. The surgical laser offers an extremely elegant and powerful solution to this problem.
Objective: To evaluate the effectiveness of erbium:YAG and argon lasers in the treatment of xanthelasma lesions.
Patients and methods: Forty patients were included in the study. Twenty patients (15 patients were bilateral with 30 eyes either in
the upper or lower lid and 5 patients were unilateral) were treated with erbium:YAG laser. Another 20 patients (10 patients were
bilateral with 20 eyes and 10 patients were unilateral) were treated with argon laser.
Results: In the majority of treated patients (either treated with erbium:YAG or argon laser), xanthelasma lesions were completely
disappeared or significantly decreased in size. Two patients showed pigmentary changes in the form of hypopigmentation with
erbium:YAG laser (one case), another case showed hyperpigmentation. No intraoperative complication was observed. No signif-
icant scar or recurrence was observed.
Conclusion: Argon laser in xanthelasma is an easy, effective, and safe method of treatment for small lesions and YAG laser is more
better for large lesions than argon laser.
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Xanthelasma is a disfiguring lesion. It appears as yellowish,
flat, and soft plaques located most commonly on the medial
portion of the eye lid. They may also be present as semisolid
or calcareous masses.1 Hyperlipidemia, thyroid dysfunction,
and diabetes mellitus are possible pathogenic triggers.2
Xanthelasma has been reported following erythroderma,
inflammatory skin disorders, and allergic contact dermatitis
in spite of normal lipid profiles.3The mechanism that initiates macrophages accumulation,
cholesterol uptake, and foam-cell formation in a normolipe-
mic patient following an inflammatory skin disorder is not
clearly understood. It has been suggested that increased
plasma lipid peroxidation (derived from oxidized low-density
lipoprotein) may lead to accumulation of cholesterol in mac-
rophages and formation of foam cells.3
Histologically, well defined deposits of doubly refractile
cholesterol and other lipids are found in macrophages which
develop into foam cells (Touton giant cells). These changese:
al.com
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cular spaces in the upper dermis of the eye lids.4
Several different methods can be used to treat xanthe-
lasma palpebrarum, including simple surgical excision which
bears a considerable risk of side effects especially an ectro-
pion and scarring,5 cryotherapy,6 chemical peeling with tri-
chloroacetic acid, with risk of irritation and pain,7 and laser
treatment. Different types of laser were tried using carbon
dioxide laser,8 argon laser,9 KTP laser,2 erbium:YAG laser,10
and pulsed dye laser.11
This study aims to evaluate the effectiveness of argon laser
and erbium:YAG laser in the treatment of patients with xan-
thelasma palpebrarum.Patients and methods
Forty patients were enrolled from the outpatient clinic of
Mansoura Ophthalmic Center from June 2010 to August
2011. The patients were randomly treated. The determina-
tion of group for the individual was randomized (dependent
on last digit of hospital ID number. If it was an even number
the patient was treated with argon laser, if it was an odd
number, the patient was treated with YAG laser). Patients
were thoroughly informed about technique, postoperative
results and possible complications and written consents were
taken from all patients. All patients were carried out in accor-
dance with the tenets of the Declaration of Helsinki (1989) of
the world medical association. The study was approved by
Mansoura University Hospital trust ethics committee.Patients preparations
Before laser application, margin of the skin lesion was out-
lined with a black pen and local infiltration anesthesia by lido-
caine HCl 2% was injected under the lesion.Table 2. Xanthelasma characters among groups.
Lesion character tics Group 1 Group 2
Size Texture Number Number
<lcm2 & soft, flat 15 12
<lcm2 & elevated, semisolid 6 7
>lcm & soft, flat 15 6
>lcm & elevated, semisolid 4 5
Total 40 30 lesion
in 35 eyes in 30 eyes
in 20 patients In 20 patients
Table 1. Demographic features among groups.
Age Group 1 Group 2
Female Male Female Male
No % No % No % No %
30–40 2 10 – – 2 10 – –
41–50 5 25 4 20 6 30 4 20
51–60 4 20 5 25 4 20 4 20
Total 11 55 9 45 12 60 8 40Settings of laser
Argon laser
Slit lamp mounted argon laser was used with the following
parameters, spot size 1000 lm, pulse duration 0.8–0.9 s, and
energy varied from 600 to 800 mw. Patient instructed to
close his eyes during laser application. Argon laser was used
in continuous mode.
Coagulation of the lesion margin is started first, then
toward the center. During laser application, subcutaneous
tissues start to shrink. At the end of treatment, xanthelasma
lesion looks smaller.
Erbium:YAG laser
Twenty patients (30 eyes) were treated with erbium:YAG
laser. For smaller lesions, spots were used with diameter of
1.6 mm, energy of 300 mJ, frequency 1 Hz and number vary-
ing in relation to the extent of the pathology. When the area
to be treated was more extensive, the frequency increased to
5 Hz while the diameter and energy remained the same. After
having bordered off the xanthelasma with a row of spots,
application was continued in a centripetal direction until the
lesion was covered throughout.Post treatment
Post treatment therapy was antibiotic-steroid ophthalmic
ointment twice daily for 2 weeks. During this period, the crust
which had formed falled within 7–14 days and newly formed
layer of skin is seen.
Photographic documentation of the lesion before laser
treatment and immediately afterward and at each of the suc-
cessive checkup visits was carried out. Follow up period was
6 months. According to size and density of the lesion, one or
more laser sessions were required. The results rating from
good to excellent (excellent means the skin of the lesion
returned normal as the rest of the surrounding skin, very
good means the skin of the lesion returned nearly normal
as the rest of the surrounding skin, good means the skin of
the lesion had acceptable color.Results
The study included 40 patients (65 eyes): 25 patients were
bilateral with 50 eyes either in the upper or lower lid and 15
patients were unilateral, so, a total of 65 eyes. Twenty
patients (35 eyes) were treated with argon laser (group 1)
and 20 patients (30 eyes) were treated with Erbium:YAG laser
(group 2). The sex, age, and lesion characteristic were
included in Tables 1 and 2.
During xanthelasma ablation either with argon or YAG
laser, there was no pain or bleeding in all patients and laser
treatment was well tolerated.
All lesions respond to laser, by formation of crust in xan-
thelasma followed by disappearance of xanthelasma or
decrease in size. During this period, no complaint was
noticed. No signs of inflammatory reaction or infection was
noticed in all cases. The newly formed layer, originally was
more pink in color and assumed a coloring homogenous with
the surrounding tissue within 4–5 weeks.
Figure 1. Effect of Argon laser treatment. a: Xanthelasma of left eye
before treatment, b: after 1 week of argon laser therapy (with transient
hyperpigmentation).
Figure 5. Erbium:YAG laser. a: Xanthelasma of left eye before treatment.
b: After one month of one session of treatment with erbium:YAG laser
(with excellent clearance).
Figure 2. Effect of Argon laser treatment. a: Xanthelasma of left eye
before treatment, b: (moderate clearance after 2nd session).
Figure 3. Effect of Argon laser treatment. a: Xanthelasma of the right
lower eyelid before treatment. b: One month after argon laser therapy
with excellent clearance of the lesion.
Figure 4. Shows effect of YAG laser treatment. a: Xanthelasma of left eye
before treatment. b: Transient hypopigmentation after one week of
erbium:YAG laser.
Table 3. Details of the results in the study.
Results Group 1 Group 2
Number
of eyes
% Number
of eyes
%
Excellent (normal) 25 71.4 20 66.7
Very good (nearly normal) 7 20 5 16.7
Good (acceptable) 2 5.7 1 3.3
Satisfactory (hardly seen scar) 1 2.8 2 6.6
Pigmentation – 2 6.6
Recurrence – –
Disfiguring scar – –
Total 35 30
118 M. Abdelkader, S.E. AlashryMost of the patients got satisfactory cosmetic appearance
with the results rating from good to excellent (Figs. 1-5 and
Table 3).Discussion
Treatment of xanthelasma is usually regarded as a cos-
metic procedure. Methods for xanthelasma removal should
have only minimal side effects. Surgical excision is often fol-
lowed by slight scarring, no matter if wound closure is
achieved through primary closure, full thickness skin graft-
ing,12,13 or granulation.5
Postoperative healing may be further complicated by
infections and poor wound healing as well as ectropion.
Extensive xanthelasmas that inflict the whole periorbital
space are not treatable surgically. Alternative to this treat-
ment is cauterization with trichloracetic acid, liquid nitrogen
or organic and non organic acids.14
However, all of these methods with risks of side effects
including persistent erythema, infection, depigmentation
and scarring. The therapeutic effect of chemical measures is
often unsatisfactory. The depth of tissue penetration by the
chemicals is hardly controllable and risk of ocular damage.15
Xanthelasmas are an ideal target for laser therapy because
of its superficial location. It is presumed that the caloric
YAG laser treatment of xanthelasma palpebrarum 119energy that originates from coagulation of the vessels within
the upper corium leads to damage of perivascular foam cells
in the lesion. The coagulation of the pathologically hyperper-
meable vessels would lead to block of the leakage of lipids
into the tissue and thereby prevents recurrence. The precise
photoablation and coagulation of the skin strata allow a gen-
tle and bloodless ablation of the lesions.16
There are different types of laser that can be used for treat-
ment of xanthelasma. Raulin and his co-workers reported ser-
ies of 52 periorbital xanthelasma treated with ultra-pulsed
carbon dioxide laser, all lesions were removed completely with
a single laser treatment. As regard for side effects, only tran-
sient pigment changes (4% hyperpigmentation, and 13% hyp-
opigmentation) with no visible scarring was observed. Three
patients (13%) developed a recurrence of xanthelasma.17
Also, Saif MYS treated 25 patients with carbon dioxide
with promising results. Most of patients got satisfactory cos-
metic appearance. In 5 lids some pigmentary (5.7%) changes
and 8 (9.1%) lids had recurrence.18
Berger and Kopera employed KTP laser (532 nm) for first
time with 85.7% of cases showed respectable reduction in
xanthelasma after 1–3 KTP laser sessions without side effects,
also 70% of their patients tolerated treatment without any
analgesia 2. The use of dye laser (585 nm) was described by
Gosepath and Mann who divided treatment in 4–5 successive
sessions, high patient acceptance with absence of complica-
tion was reported.19
Another type of laser for treating skin lesions is erbiu-
m:YAG. Despite it is being of the pulsed type, studies have
shown that it causes continuous ablation that starts with a
slight delay in relation to the pulsation and lasts until the lat-
ter ends. The first studies on its ablation effect on the skin
showed a linear increase in the rate of ablation with a radia-
tion exposure threshold of 1 J/cm2 and slop efficiency of
6.7 Mm/J/cm2.20
Erbium:YAG laser which was used in this study, is an instru-
ment that allows surface ablation of skin with minimum heat
effect, only operative inside the skin without involving the
melanocytes and blood vessels. It is characterized by a wave
length 2.94 lm that corresponds to maximum absorption of
water. Since approximately 77% of skin consists of water, this
absorption was the optimal condition for the ablation effect.
When the energy administered reaches the ablation thresh-
old, the water vaporizes at ultrasonic speed, removing the
tissue with the sound phenomenon of a sharp bang.10
Borelli and Kaudewitz treated 33 xanthelasma lesions with
erbium:YAG laser with promising results as all lesions were
removed without hyperpigmentation or scarring.10 Also,
Mannino and colleagues reported good esthetic results in
30 female patients, 70 xanthelasmas treated with erbiu-
m:YAG laser without leaving scars and/or dyschromia.21
Kaufman and Hibst treated 9 xanthelasmas in 4 patients
with erbium:YAG laser using spots with a diameter 2 mm
and energy of 315 mJ. Only in 2 particularly extensive
patients, atrophic scars remained after 4 months.22
Drnovsek-Olup and Vedlin reported that in 32 xanthelas-
mas of 8 patients treated with erbium:YAG laser and with
average follow up of 3 months, an optimum results was
achieved in 100% of patients. For all the lesions, one single
session of treatment was sufficient.23
In our study, 30 xanthelasma lesions in 30 eyes in 20
patients were treated with erbium:YAG laser. Only 2 patientsdeveloped hypopigmentation. All patients were needed only
one session. The treatment is well tolerated by patients. The
procedure was done in sitting or lying position.
By using slit lamp mounted argon laser, Hintschich
reported that in 32 xanthelasma lesions treated with green
argon, good and very good cosmetic results was achieved
in 80% of cases. There were no intra or postoperative compli-
cation or functional scars. Recurrence occurred in 14 out of
25 lids after 12–16 month of follow up.16
Ruban and colleagues treated 25 patients with 101 xan-
thelasma by slit lamp blue-green argon laser. Cosmetic
results was good in 83% of cases without either scarring or
dyschromia and in 13.3% of patients, there was minimal scar-
ring/slight dyschromia while in 3.3% of patients there was vis-
ible scarring/marked dyschromia.24
Basar and co-workers reported 85% good, 10% fair and
5% poor cosmetic results in 40 eyes with xanthelasma treated
with argon laser.25
In this study, 40 xanthelasma lesions, 35 eyes in 20
patients were treated with argon laser. 71.4% had excellent
results, 20% very good, 5.7% good, 2.8% had satisfactory
results. Small lesion <1 cm2 had excellent results in all cases
regardless of its firmness. Large lesions needed more than
one session with 2 weeks apart.
Hintschich showed that effectiveness of argon laser in xan-
thelasma is due to its thermal effect when laser energy
absorbed with skin chromospheres, it is converted into heat
and by using sublesional probe to measure the temperature
it was elevated to 50–60 which alter the foam cells in xanthe-
lasma and coagulated blood vessel.26 Sampath et al. showed
that histological changes of xanthelasma after argon laser are
consistent with a superficial photocoagulation of the upper
skin levels to a depth of 1 mm dermis preserving dermal
appendages and aiding in the rapid healing of the wound
without scar.27
Major disadvantage of argon laser photocoagulation as
reported in literature was significant recurrence rate. One
study has reported that 14 recurrences out of 32 treated
lesions were within the first 12–16 months after argon laser.26
Baser and coworkers were also reported that 6 out of 40 trea-
ted with argon laser were recurred after one year of
treatment.25
Most of recurrences were found to be developed from the
margin of xanthelasma, so margin of xanthelasma should be
treated well. In this study, there was no recurrence which may
be due to relatively short follow up period (6 months).
In summary, laser represents a valid alternative to the more
traditional methods of treating xanthelasma because of the
simplicity and speed of performance, minimal postoperative
treatment and the positive functional and esthetic results.Conflict of interest
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Supplementary data associated with this article can be
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